Affimed (AFMD) Stock
Healthcare sector company. Here's the price, business snapshot, and what's worth knowing about Affimed in September 2026.
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
About This Stock
AFFIMED NV
AFMD
Current Price
$0.18
Potential 12 Month Profit
8,806.17%
Sector
Healthcare
Industry
Biotechnology & Medical Research
Ticker
AFMD
Market Cap
$4.25M
Potential 12 Month Profit
8,806.17%
Sector
Healthcare
Industry
Biotechnology & Medical Research
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying AFFIMED NV stock, expecting significant growth potential towards the target price.
Financial Health
Affimed NV has low revenue and book value per share, indicating potential financial challenges.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.